Tourmaline Bio, Inc. financial data

Symbol
TRML on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
27 West 24 Th Street, Suite 702, New York, NY
Fiscal year end
December 31
Former names
Talaris Therapeutics, Inc. (to 10/18/2023)
Latest financial report
10-Q - Q1 2025 - May 2, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.71K % +27.5%
Debt-to-equity 2.46 % -60.5%
Return On Equity -26.8 % +34.5%
Return On Assets -26.1 % -19.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.7M shares +0.15%
Common Stock, Shares, Outstanding 25.7M shares +0.15%
Entity Public Float 294M USD +227%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 25.7M shares +6.69%
Weighted Average Number of Shares Outstanding, Diluted 25.7M shares +6.69%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 75.9M USD +102%
General and Administrative Expense 22.6M USD +26.7%
Operating Income (Loss) -98.4M USD -77.6%
Net Income (Loss) Attributable to Parent -82.9M USD -72.9%
Earnings Per Share, Basic -3.23 USD/shares -183%
Earnings Per Share, Diluted -3.23 USD/shares -183%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.3M USD -64.1%
Marketable Securities, Current 79.9M USD -54.4%
Cash, Cash Equivalents, and Short-term Investments 243M USD +13%
Other Assets, Current 1.49M USD +92.3%
Assets, Current 258M USD -14%
Property, Plant and Equipment, Net 59K USD -21.3%
Operating Lease, Right-of-Use Asset 170K USD -48%
Intangible Assets, Net (Excluding Goodwill) 0 USD
Goodwill 0 USD
Other Assets, Noncurrent 2.9M USD +141%
Assets 287M USD -20%
Accounts Payable, Current 2.24M USD +15.4%
Accrued Liabilities, Current 5.19M USD +94.6%
Liabilities, Current 7.62M USD +57.9%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 13K USD -74%
Liabilities 7.64M USD +51.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 227K USD
Retained Earnings (Accumulated Deficit) -158M USD -110%
Stockholders' Equity Attributable to Parent 280M USD -21%
Liabilities and Equity 287M USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.7M USD -45.3%
Net Cash Provided by (Used in) Financing Activities 562K USD -99.7%
Net Cash Provided by (Used in) Investing Activities 25.9M USD
Common Stock, Shares Authorized 140M shares 0%
Common Stock, Shares, Issued 25.7M shares +0.15%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.82M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.6M USD -63.9%
Deferred Tax Assets, Valuation Allowance 46.4M USD +36.2%
Deferred Tax Assets, Gross 49.5M USD +37.9%
Operating Lease, Liability 244K USD -41.2%
Depreciation 12K USD +20%
Payments to Acquire Property, Plant, and Equipment 9K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -82.4M USD -71%
Lessee, Operating Lease, Liability, to be Paid 265K USD -45.5%
Property, Plant and Equipment, Gross 132K USD +7.32%
Operating Lease, Liability, Current 196K USD -12.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 38K USD -83.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 227K USD +2.72%
Operating Lease, Weighted Average Discount Rate, Percent 0.16 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21K USD -70.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 11.2M USD +105%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 200K USD -77.8%
Additional Paid in Capital 438M USD +1.89%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 436K USD +46.8%
Deferred Tax Assets, Net of Valuation Allowance 3.1M USD +68%
Share-based Payment Arrangement, Expense 7.48M USD +10.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%